Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer
Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
Clinically, there has been extensive experience with topotecan and cisplatin. Recently,
several investigators have evaluated the combination of paclitaxel, cisplatin and topotecan.
As expected, myelosuppression was the dose-limiting factor. Herben et al recently reported
the results of a phase I trial using the combination of paclitaxel, cisplatin, and topotecan
as first line therapy in advanced stage ovarian cancer. Interestingly, the authors could not
achieve a dose of topotecan that would be considered "optimal" for the treatment of relapsed
disease in a single-agent fashion. The inability to utilize a therapeutic dose when combined
with either platinum or paclitaxel has been demonstrated in previous reports and affirms the
bone marrow suppressive effect. The clinical response rate from this trial was reported as
86.7%.